Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis - Report of three cases

Zeitschrift fur Gastroenterologie

Volumn 35, Issue 7, 1997, Pages 571-578

  Kanzler, S ^a   Gerken, G ^a   Dienes, H P ^a   Meyer Zum Buschenfelde K H ^a   Lohse, A W ^a,b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Autoimmune hepatitis; Cyclophosphamide; Immunosuppressive therapy; Side effects

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; LIVER ENZYME; MESNA; PREDNISOLONE;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; CASE REPORT; DOSE RESPONSE; FEMALE; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER BIOPSY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PANCREATITIS; REMISSION; VOMITING;

ADULT; ANTI-INFLAMMATORY AGENTS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER FUNCTION TESTS; LONG-TERM CARE; MALE; MIDDLE AGED; PREDNISOLONE;

EID: 8544229063     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Sherlock S, Blanchi FB, Desmet VJ, Main J, Pagliaro L. Classification of autoimmune chronic active hepatitis. J Gastroenterol Hepatol 1990; 5: 360-1
2. Meyer zum Büschenfelde KH, Lohse AW, Manns M, Poralla T. Autoimmunity and liver disease. Hepatology 1990; 12: 354-60
3. Johnson PJ, McFarlane IG, Eddleston ALWF. The natural course and heterogeneity of autoimmune-type chronic active hepatitis. Semin Liver Dis 1991; 11: 187-96
4. McFarlane IG, Eddlestone ALWF. Chronic active hepatitis. In: Targan SR, Shanahan F (eds.). Immunology and immunpathology of the liver and the gastrointestinal tract. New York, Igaku-Shoin, 1989: 281-304
5. Czaja AJ. Autoimmune chronic active hepatitis. In: Czaja AJ, Dickson ER (eds.). Chronic active hepatitis: The Mayo Clinic experience. New York, Marcel Dekker Inc. 1986: 105-26
6. Johnson PJ, McFarlane IG. Meeting report: International autoimmune hepatitis group. Hepatology 1993; 18: 998-1005
7. Meyer zum Büschenfelde KH, Lohse AW. Autoimmune hepatitis. N Engl J Med 1995; 333: 1004-5
8. Copenhagen Study Group for Liver Diseases. Effect of prednisolone on the survival of patients with cirrhosis of the liver. Lancet 1969; 1: 119-21
9. Cook CC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in chronic active hepatitis. Q J Med 1971: 40: 159-85
10. Soloway RD, Summerskill WHJ, Baggenstoss AH et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820-33
11. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisolone and azathioprine in active chronic hepatitis. Lancet 1973; 1: 735-7
12. Maddrey WC, Combes B. Therapeutic concepts for the management of idiopathic autoimmune chronic active hepatitis. Semin Liver Dis 1991; 11: 248-55
13. Czaja AJ. Treatment of autoimmune hepatitis. In: Nishioka M, Toda G, Zentya M (eds.). Autoimmune hepatitis. Elsevier Science BV 1994: 283-304
14. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 333: 958-63
15. Kirk AP, Jain S, Pocock S, Thomas HC, Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980; 21: 78-83
16. Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987; 93: 890-3
17. Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hcpatol 1994; 21: 1040-7
18. Van Thiel DH, Wright H. Carroll P et al. Tacrolismus: A potential new treatment for autoimmune chronic active hepatitis: Results of an open-label preliminary trial. Am J Gastroenterol 1995: 90: 771-6
19. Stange EF, Modigliani R, Pena AS et al and the European Study Group. European trial of Cyclosporine in chronic active Crohn's disease: A 12-month study. Gastroenterology 1995; 109: 774-82
20. Sandborn WJ. Cyclosporine therapy for inflammatory bowel disease: Definitive answers and remaining questions. Gastroenterology 1995: 109: 1001-3
21. Donaldson PT, Doherty D. Hayllar KM et al. Susceptibility to autoimmune chronic hepatitis: Human leukocyte antigens DR 4 and Al-B8-DR3 are independent risk factors. Hepatology 1991; 13: 701-6
22. Gilmore IT. Cowan RE, Axon ATR, Thomson RPH. Controlled trial of cyclophosphamide in active chronic hepatitis. Br Med J 1979: 1(6171): 1120-1
23. Pengelly CDR, Jennings RC. Active chronic hepatitis (letter). Lancet 1978: 2 (8090): 632-3
24. Fauci AS, Haynes BF. Katz P, Wolff SM. Wegener's granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85
25. Plotz PH, Klippel JH, Decker JL et al. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematodes or rheumatoid arthritis. Ann Intern Med 1979; 91: 221-3
26. Worth PHL. Cyclophosphamide and the bladder. Br Med J 1971; 2: 182
27. Schein PS, Winokur ST. Immunosuppressive and cytotoxic chemotherapy: Long-term complications. Ann Intern Med 1975: 82: 84-95
28. Kahn MF. Ariel J. Bloch-Michel H et al. Acute leukaemias after treatment using cytotoxic agents for rheumatological purposes. 19 cases among 2006 patients. Presse Méd 1979; 8: 1393-7
29. Fung JJ. Alessiani M. Abu-Elmagd KA et al. Adverse effects associated with the use of FK 506. Transplant Proc 1991; 23: 3105-8
30. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolismus: A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993: 46(4): 746-94
31. Faulds D, Goa KL, Benfield P. Cyclosporin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993; 45(6): 953-1040
32. Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: A 20 year follow-up study. Ann Rheum Dis 1988; 47: 988-92
33. Puri CP, Campbell RA. Cyclophosphamide and malignancy. Lancet 1977; 1: 1306
34. Wang KK, Czaja AJ, Beaver SJ, Go VLW. Extrahepatic malignancy following long-term immunosuppresive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Hepatology 1989; 10: 39-43
35. Nalesnik MA, Jaffe R, Starzl TE et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisolone immunosuppression. Am J Path 1988; 133: 173-92
36. Reyes J. Tzakis A, Green M et al. Posttransplant lymphoproliferative disorders occurring under primary therapy FK 506 immunosuppression. Transplant Proc 1991; 23: 3044-6
37. Caell MC, Schoenfield LJ, Summerskill WHJ. Classification and treatment of chronic active liver disease. Gastroenterology 1968; 55: 724-9
38. Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid- treated severe autoimmune chronic active hepatitis. Gastroenterology 1988: 448-53